The Company has more than 40 proprietary and partnered product candidates in development
Ablynx participates and presents at IR and scientific conferences
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX.
CORRECTION TRANSPARENCY NOTIFICATION - ADRIANUS VAN HERK ANNOUNCES 3.02% SHAREHOLDING IN ABLYNX16 June 2016
VAN HERK INVESTMENTS ANNOUNCE 3.02% SHAREHOLDING IN ABLYNX16 June 2016
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")14 June 2016
TITAN study - Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura